Press Releases

Endonovo Therapeutics to Develop Next Generation, Off-The-Shelf, Cell Free Regenerative Products

Download PDF

Dr. Leonard Makowka, a Leading Authority in Hepatic Science, Joins Endonovo Therapeutics as Its Chief Medical Officer

LOS ANGELES, CA--(Marketwired - Jun 11, 2014) - Endonovo Therapeutics, Inc. (OTCQB:ENDV) ("Endonovo" or the "Company"), a biotechnology company developing innovative regenerative therapies, announced today that it has created technologies to pursue the development and manufacturing of next generation regenerative products that no longer require the administration of stem cells. Endonovo's "Cell Free" products will harness the biological molecules secreted by cells to create truly "off-the-shelf" therapeutics that can be delivered to patients in a much timelier manner than is possible with autologous and allogeneic stem cell therapies.

There are currently more than 300 mesenchymal stem cell clinical trials underway to treat a wide range of pathological conditions listed on the database. These clinical trials are still based on the transplantation of mesenchymal stem cells. Endonovo is developing therapies that may mitigate many of the current drawbacks of cell-based therapies, such as the low survival and engraftment rate of transplanted stem cells, the risk of occlusion in microvasculature, and unregulated growth, such as hyper-innervation or ossification and/or calcification in the body.

"Cell Free" regenerative products may also mitigate many of the limitations to the commercialization of stem cell therapies, such as the manufacturing, storage and delivery of viable cells. "Cell Free" regenerative products are commercially more attractive because they are simpler to manufacture, easier to store and maintain their therapeutic potency for longer periods of time when compared to stem cells.

Additionally, Endonovo Therapeutics announced that it has appointed Dr. Leonard Makowka, M.D., Ph.D., to serve as the Company's Chief Medical Officer. Dr. Makowka was formerly the Chairman of the Department of Surgery and Director of Transplantation Services at Cedars Sinai Medical Center in Los Angeles, CA, and served as Professor of Surgery at the UCLA School of Medicine. He was also Executive Director of the Comprehensive Liver Disease Center, which used a multiple disciplinary approach to the treatment of liver disease, at St. Vincent's Medical Center in Los Angeles, CA. He has published over 400 articles and chapters in both clinical and basic scientific research and has been regarded as a leading authority in hepatic science. Dr. Makowka has also served as a board member of various public and private healthcare and life science companies.

"We are very pleased to welcome Dr. Makowka to the Endonovo team," said Endonovo Therapeutics CEO, Alan Collier. "His experience and expertise will be a tremendous asset in the development of 'cell-free' therapeutics that can promote the regeneration of tissues without the need to inject stem cells into the body, which would result in safer, more effective therapies, lower costs and the saving of lives."

"I am excited to join Endonovo Therapeutics and help the company develop its 'cell-free' therapeutic platform," stated Dr. Leonard Makowka, Chief Medical Officer at Endonovo Therapeutics. "Although it is early in the developmental lifecycle, we are excited about the development of first-in-class, 'cell free' regenerative products that can protect and stimulate the regeneration of tissues. These products would be truly 'off-the-shelf' therapies that could be quickly administered following organ injuries, such as a heart attack, a stroke, acute and/or chronic liver disease and the 'aging' of organs, in order to protect the organ and begin healing it." 

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a publicly traded biotechnology company developing off-the-shelf, cell free regenerative products and non-invasive, bioelectronic therapies designed to extend and enhance the human life by regenerating tissues and organs that have become injured or damaged due to disease and age. The Company is developing therapies for various inflammatory, autoimmune and degenerative diseases using biomolecules secreted from cells and Time-Varying Electromagnetic Fields (TVEMF).

Safe Harbor Statement

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release. 

Investor Relations Contact:

Mr. Ramiro Contreras
Vice President of Corporate Development
Endonovo Therapeutics, Inc.